Cornerstone Therapeutics Inc.’s largest shareholder, Italian pharma Chiesi Farmaceutici SpA, sweetened its original bid to purchase the specialty pharma’s remaining shares, settling on $9.50 each in cash. Read More
The European Medicines Agency (EMA) is introducing a sweeping reorganization, which it hopes will lead to greater efficiency and effectiveness despite the budgetary constraints it is facing, as the European Union continues to battle through an economic crisis that has now lasted for half a decade. Read More
Following its dramatic primary endpoint miss in February, Celsion Corp.’s HEAT study offers some hope in a post-hoc analysis including positive overall survival results in a subgroup of participants. Read More
LONDON – UK Members of Parliament (MPs) added their voices to the clamor for greater transparency of clinical trial results, describing the current situation as “unacceptable” and calling for the publication of clinical study reports and moves to provide controlled access to patient-level data. Read More
LONDON – Circassia Ltd. is looking for shareholders’ backing for a Phase III trial of its house dust mite allergy treatment after reporting positive results in a Phase II study, with subjects who received the most effective dose showing a significant reduction in symptoms of allergic rhinitis at one year. Read More
Researchers have deciphered the crystal structure of the HIV co-receptor bound to an indirect inhibitor of viral entry, Celsentri/Selzentry (maraviroc, ViiV Healthcare Co.). The findings could offer valuable clues for how to design the next generation of such inhibitors. Read More
• Emmaus Life Sciences Inc., of Torrance, Calif., said it raised approximately $7.5 million in gross proceeds from a private placement to accredited investors, including two institutional investors. Read More
• Benu Biopharma, of Natick, Mass., said it has established Benu Bioventures, a biopharmaceutical investment initiative to fund and develop preclinical stage pharmaceutical investments to the human proof-of-concept stage. Read More
• Pluristem Therapeutics Inc., of Haifa, Israel, said the FDA lifted the clinical hold placed June 4 on the company’s Phase II intermittent claudication study, stating that the company had addressed all the clinical hold issues and may proceed with the trial. Read More
• Actavis Inc. of Parsippany, N.J., launched a generic version of Liboderm (lidocaine topical patch 5 percent) under an agreement with Endo Pharmaceuticals Inc., of Malvern, Pa., and Teikoku Seiyaku Co. Ltd., of Kagawa, Japan. Read More
